{"id":4207,"date":"2018-04-27T09:29:33","date_gmt":"2018-04-27T13:29:33","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4207"},"modified":"2018-04-27T09:29:33","modified_gmt":"2018-04-27T13:29:33","slug":"aslan-pharmaceuticals-limited-ipo-preview-asln","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/aslan-pharmaceuticals-limited-ipo-preview-asln\/","title":{"rendered":"ASLAN Pharmaceuticals Limited #IPO Preview ($ASLN)"},"content":{"rendered":"

\"Microsoft<\/a><\/p>\n

Company: ASLAN Pharmaceuticals Limited<\/strong>
\nSymbol: ASLN
\nDescription: They are a clinical-stage oncology-focused biopharmaceutical company based in Singapore developing novel therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
\nShares: 7.5 million ADSs
\nPrice Range: $8.05-$8.05
\nTrade Date: 5\/3
\nUnderwriter(s): Leerink Partners, Piper Jaffray
\nCo-Manager: BTIG, H.C. Wainwright & Co., CLSA
\nTerms Added: 4-16-18
\nNote: Their ordinary shares are currently listed on the Taipei Exchange, or TPEx.<\/p>\n

Link to Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>:<\/p>\n

Their Asia development platform is designed to enable them to accelerate the development of drugs to treat these diseases. Their portfolio is comprised of four product candidates which target: validated growth pathways applied to new patient segments; novel immune checkpoints; and novel cancer metabolic pathways.<\/p>\n

Their lead program,\u00a0varlitinib,\u00a0is a reversible small molecule pan-human epidermal growth factor receptor,\u00a0or\u00a0pan-HER,\u00a0inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4.\u00a0Varlitinib\u00a0is currently being studied in a global pivotal clinical trial for biliary tract cancer for which they expect to report topline data in 2019. They are also conducting a global Phase 2\/3 clinical trial of\u00a0varlitinib\u00a0for gastric cancer for which they expect to report topline Phase 2 data in the second half of 2018.<\/p>\n

They focus on cancers, such as gastric cancer and biliary tract cancer, which are orphan diseases in the United States and Europe for which there are few, if any, approved therapies.<\/p>\n

\"ASLN.drugs\"<\/a><\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: ASLAN Pharmaceuticals Limited Symbol: ASLN Description: They are a clinical-stage oncology-focused biopharmaceutical company based in Singapore developing novel therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Shares: 7.5 million ADSs Price Range: $8.05-$8.05 Trade Date: 5\/3 Underwriter(s): Leerink Partners,[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1501],"class_list":["post-4207","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-asln"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4207"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4207\/revisions"}],"predecessor-version":[{"id":4233,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4207\/revisions\/4233"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}